Status: Recruiting
NG004 in Spinal Cord Injury Patients
This is the FIH, multicenter, open-label, sequential, multiple ascending dose trial of NG004 in patients with acute incomplete cervical SCI. The trial will evaluate the safety, tolerability, and PK of 4 dose regimens of NG004, and will evaluate the maximum tolerated dose of NG004.
Participants needed: 21
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: NovaGo Therapeutics AGUpdated: Feb 10, 2025Locations: 6
Eligibility criteria
Acute incomplete cervical SCI (Neurological level of injury C1 ≤ lesion ≤ C8) wi... [+3]
Trauma caused by ballistic or other injury that directly penetrates the spinal c... [+15]